Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: A prospective observational case series

Gregory A. Nuttall, William C. Oliver, Paula J. Santrach, Robert D. McBane, Daniel B. Erpelding, Christina L. Marver, Kenton J Zehr

Research output: Contribution to journalArticle

Abstract

Heparin-induced thrombocytopenia with thrombosis (HITT) type II is a life-threatening complication of heparin therapy that most often occurs after 5-10 days of exposure to heparin. Anticoagulation is a significant concern for patients with HITT type II being prepared for cardiac surgery requiring cardiopulmonary bypass (CPB). We report a case series of 12 patients with a history HITT type II who underwent CPB and cardiac surgery. Six patients did not express the antibody that mediates HITT type II immediately before surgery. Heparin was used as the anticoagulant for the duration of CPB only, and all these patients did well without thrombotic complications. Six patients expressed the antibody that mediates HITT type II immediately before surgery. Hirudin was used as the anticoagulant for CPB in these patients. The ecarin clotting time was used to guide hirudin therapy during CPB. The patients receiving hirudin did well, but they had a large amount of bleeding, required transfusions of multiple allogeneic blood products, and had a frequent rate of reexploration of the mediastinum after CPB.

Original languageEnglish (US)
Pages (from-to)344-350
Number of pages7
JournalAnesthesia and Analgesia
Volume96
Issue number2
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Cardiopulmonary Bypass
Thrombocytopenia
Thoracic Surgery
Heparin
Thrombosis
Hirudins
Hirudin Therapy
Anticoagulants
Antibodies
Mediastinum
History
Hemorrhage

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass : A prospective observational case series. / Nuttall, Gregory A.; Oliver, William C.; Santrach, Paula J.; McBane, Robert D.; Erpelding, Daniel B.; Marver, Christina L.; Zehr, Kenton J.

In: Anesthesia and Analgesia, Vol. 96, No. 2, 01.02.2003, p. 344-350.

Research output: Contribution to journalArticle

Nuttall, Gregory A. ; Oliver, William C. ; Santrach, Paula J. ; McBane, Robert D. ; Erpelding, Daniel B. ; Marver, Christina L. ; Zehr, Kenton J. / Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass : A prospective observational case series. In: Anesthesia and Analgesia. 2003 ; Vol. 96, No. 2. pp. 344-350.
@article{9b1ae00238c8413f935ac964101cf55b,
title = "Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: A prospective observational case series",
abstract = "Heparin-induced thrombocytopenia with thrombosis (HITT) type II is a life-threatening complication of heparin therapy that most often occurs after 5-10 days of exposure to heparin. Anticoagulation is a significant concern for patients with HITT type II being prepared for cardiac surgery requiring cardiopulmonary bypass (CPB). We report a case series of 12 patients with a history HITT type II who underwent CPB and cardiac surgery. Six patients did not express the antibody that mediates HITT type II immediately before surgery. Heparin was used as the anticoagulant for the duration of CPB only, and all these patients did well without thrombotic complications. Six patients expressed the antibody that mediates HITT type II immediately before surgery. Hirudin was used as the anticoagulant for CPB in these patients. The ecarin clotting time was used to guide hirudin therapy during CPB. The patients receiving hirudin did well, but they had a large amount of bleeding, required transfusions of multiple allogeneic blood products, and had a frequent rate of reexploration of the mediastinum after CPB.",
author = "Nuttall, {Gregory A.} and Oliver, {William C.} and Santrach, {Paula J.} and McBane, {Robert D.} and Erpelding, {Daniel B.} and Marver, {Christina L.} and Zehr, {Kenton J}",
year = "2003",
month = "2",
day = "1",
doi = "10.1097/00000539-200302000-00009",
language = "English (US)",
volume = "96",
pages = "344--350",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass

T2 - A prospective observational case series

AU - Nuttall, Gregory A.

AU - Oliver, William C.

AU - Santrach, Paula J.

AU - McBane, Robert D.

AU - Erpelding, Daniel B.

AU - Marver, Christina L.

AU - Zehr, Kenton J

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Heparin-induced thrombocytopenia with thrombosis (HITT) type II is a life-threatening complication of heparin therapy that most often occurs after 5-10 days of exposure to heparin. Anticoagulation is a significant concern for patients with HITT type II being prepared for cardiac surgery requiring cardiopulmonary bypass (CPB). We report a case series of 12 patients with a history HITT type II who underwent CPB and cardiac surgery. Six patients did not express the antibody that mediates HITT type II immediately before surgery. Heparin was used as the anticoagulant for the duration of CPB only, and all these patients did well without thrombotic complications. Six patients expressed the antibody that mediates HITT type II immediately before surgery. Hirudin was used as the anticoagulant for CPB in these patients. The ecarin clotting time was used to guide hirudin therapy during CPB. The patients receiving hirudin did well, but they had a large amount of bleeding, required transfusions of multiple allogeneic blood products, and had a frequent rate of reexploration of the mediastinum after CPB.

AB - Heparin-induced thrombocytopenia with thrombosis (HITT) type II is a life-threatening complication of heparin therapy that most often occurs after 5-10 days of exposure to heparin. Anticoagulation is a significant concern for patients with HITT type II being prepared for cardiac surgery requiring cardiopulmonary bypass (CPB). We report a case series of 12 patients with a history HITT type II who underwent CPB and cardiac surgery. Six patients did not express the antibody that mediates HITT type II immediately before surgery. Heparin was used as the anticoagulant for the duration of CPB only, and all these patients did well without thrombotic complications. Six patients expressed the antibody that mediates HITT type II immediately before surgery. Hirudin was used as the anticoagulant for CPB in these patients. The ecarin clotting time was used to guide hirudin therapy during CPB. The patients receiving hirudin did well, but they had a large amount of bleeding, required transfusions of multiple allogeneic blood products, and had a frequent rate of reexploration of the mediastinum after CPB.

UR - http://www.scopus.com/inward/record.url?scp=0037302940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037302940&partnerID=8YFLogxK

U2 - 10.1097/00000539-200302000-00009

DO - 10.1097/00000539-200302000-00009

M3 - Article

C2 - 12538175

AN - SCOPUS:0037302940

VL - 96

SP - 344

EP - 350

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 2

ER -